JP2023548303A5 - - Google Patents
Info
- Publication number
- JP2023548303A5 JP2023548303A5 JP2023526030A JP2023526030A JP2023548303A5 JP 2023548303 A5 JP2023548303 A5 JP 2023548303A5 JP 2023526030 A JP2023526030 A JP 2023526030A JP 2023526030 A JP2023526030 A JP 2023526030A JP 2023548303 A5 JP2023548303 A5 JP 2023548303A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- dosage form
- venetoclax
- sedazulidine
- decitabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026042423A JP2026083415A (ja) | 2020-10-29 | 2026-03-16 | 癌を処置する為の医薬組成物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107010P | 2020-10-29 | 2020-10-29 | |
| US63/107,010 | 2020-10-29 | ||
| PCT/US2021/056809 WO2022093930A1 (en) | 2020-10-29 | 2021-10-27 | Pharmaceutical compositions and methods of using the same for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026042423A Division JP2026083415A (ja) | 2020-10-29 | 2026-03-16 | 癌を処置する為の医薬組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548303A JP2023548303A (ja) | 2023-11-16 |
| JP2023548303A5 true JP2023548303A5 (enExample) | 2024-10-08 |
Family
ID=81384423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526030A Pending JP2023548303A (ja) | 2020-10-29 | 2021-10-27 | 癌を処置する為の医薬組成物及びその使用方法 |
| JP2026042423A Pending JP2026083415A (ja) | 2020-10-29 | 2026-03-16 | 癌を処置する為の医薬組成物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026042423A Pending JP2026083415A (ja) | 2020-10-29 | 2026-03-16 | 癌を処置する為の医薬組成物及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12697347B2 (enExample) |
| EP (1) | EP4237094A4 (enExample) |
| JP (2) | JP2023548303A (enExample) |
| KR (1) | KR20230097034A (enExample) |
| CN (2) | CN122182592A (enExample) |
| AU (1) | AU2021369508B2 (enExample) |
| CA (1) | CA3188316A1 (enExample) |
| MX (1) | MX2023003305A (enExample) |
| TW (1) | TW202227096A (enExample) |
| WO (1) | WO2022093930A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| AU2024265282A1 (en) * | 2023-05-02 | 2025-12-18 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| US9834576B2 (en) | 2013-10-29 | 2017-12-05 | Otsuka Pharmaceutical Co., Ltd. | Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines |
| US10683552B2 (en) | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
| US11224610B2 (en) | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| SG11202108523UA (en) * | 2019-03-25 | 2021-09-29 | Otsuka Pharma Co Ltd | Antitumor composition |
| MX2022005811A (es) | 2019-11-13 | 2022-06-08 | Taiho Pharmaceutical Co Ltd | Sal novedosa de compuesto de terfenilo. |
| WO2021113688A1 (en) | 2019-12-05 | 2021-06-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Combination therapies for treatment of myelodysplastic syndrome |
| EP4090335A1 (en) | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| LT4069254T (lt) | 2020-02-25 | 2024-10-10 | Otsuka Pharmaceutical Co., Ltd. | Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną |
| JP2023548303A (ja) | 2020-10-29 | 2023-11-16 | 大塚製薬株式会社 | 癌を処置する為の医薬組成物及びその使用方法 |
| JP2024521824A (ja) | 2021-05-27 | 2024-06-04 | ヴァンダービルト ユニヴァーシティ | マクロライド化合物 |
| MX2024003537A (es) | 2021-09-21 | 2024-05-03 | Otsuka Pharma Co Ltd | Metodos de tratamiento de los sindrome mielodisplasico con decitabina y cedazuridina. |
-
2021
- 2021-10-27 JP JP2023526030A patent/JP2023548303A/ja active Pending
- 2021-10-27 AU AU2021369508A patent/AU2021369508B2/en active Active
- 2021-10-27 MX MX2023003305A patent/MX2023003305A/es unknown
- 2021-10-27 WO PCT/US2021/056809 patent/WO2022093930A1/en not_active Ceased
- 2021-10-27 CN CN202610493906.4A patent/CN122182592A/zh active Pending
- 2021-10-27 EP EP21887422.0A patent/EP4237094A4/en active Pending
- 2021-10-27 US US18/250,674 patent/US12697347B2/en active Active
- 2021-10-27 TW TW110139922A patent/TW202227096A/zh unknown
- 2021-10-27 KR KR1020237014585A patent/KR20230097034A/ko active Pending
- 2021-10-27 CN CN202180052939.0A patent/CN116018145A/zh active Pending
- 2021-10-27 CA CA3188316A patent/CA3188316A1/en active Pending
-
2026
- 2026-03-16 JP JP2026042423A patent/JP2026083415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (enExample) | ||
| JP2022180461A5 (enExample) | ||
| Kuriakose et al. | Potential therapeutic strategies for hypertension‐exacerbated cardiotoxicity of anticancer drugs | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2024516795A5 (enExample) | ||
| JP2003533485A5 (enExample) | ||
| JP2024516363A5 (enExample) | ||
| CA3043456A1 (en) | Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer | |
| WO1995028939A1 (en) | Medicinal composition as a remedy for nonsmall cell lung cancer | |
| WO2024183644A1 (zh) | 包含阿兹夫定的抗肿瘤药物组合物 | |
| JP2024016209A5 (enExample) | ||
| JP2001513110A (ja) | 腫瘍治療方法 | |
| TW202435896A (zh) | 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物 | |
| KR101572529B1 (ko) | 암 치료를 위한 육산화사비소의 병용요법 | |
| JP2025511402A5 (enExample) | ||
| JP2024531799A5 (enExample) | ||
| JP2025511401A5 (enExample) | ||
| CN107260734B (zh) | 一种具有抗肺癌作用的复方药物组合物及其用途 | |
| JP6895688B2 (ja) | 血液がんの新規治療法及び新規治療剤 | |
| CA3079031C (en) | Formulation containing a-decarbonized-5-alpha androstane compound for increasing white blood cell and use thereof | |
| RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| JP2025511403A5 (enExample) | ||
| CN104146999B (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| JP2024518426A5 (enExample) | ||
| Chang et al. | Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis |